Clinical Trials Logo

Filter by:
NCT ID: NCT05579730 Completed - Clinical trials for Allergic Conjunctivitis

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

Start date: November 18, 2022
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis:

NCT ID: NCT05579691 Completed - Friedreich Ataxia Clinical Trials

A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

Start date: September 21, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) administration of CTI-1601 over 28 days in subjects with Friedreich's ataxia (FRDA).

NCT ID: NCT05579652 Completed - Incisional Hernia Clinical Trials

Change in Fascial Tension in Open Abdomens

Start date: October 17, 2022
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to quantitatively measure the change in tension of the abdominal wall over time in subjects with open abdomens using a tensiometer.

NCT ID: NCT05579574 Completed - Clinical trials for Healthy Participants

A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants

Start date: October 21, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of multiple doses of BMS-986322 on the pharmacokinetics (PK) of Loestrin components in healthy female participants.

NCT ID: NCT05579431 Completed - Clinical trials for Alpha 1-Antitrypsin Deficiency

A Phase 1, First-in-human Study of VX-634

Start date: October 13, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-634 at various doses.

NCT ID: NCT05579093 Completed - Delirium Clinical Trials

Clinical Investigation of an Eye-Tracking Device as a Predictor of Delirium in the Recovery Room After Surgery With General Anesthesia

Start date: October 1, 2019
Phase:
Study type: Observational

Neurotrack™ is an FDA-approved device for measuring and tracking cognitive decline, as may occur with age-related cognitive decline and Alzheimer's disease. The device uses a webcam (World Wide Web enabled camera) to assess eye-tracking as the subject views black-and-white images on the computer screen. The test takes less than 5 minutes to complete. This study will examine the feasibility and utility of pre-operative assessment of cognition using Neurotrack™ technology. The predictive value of Neurotrack™ will be compared to our previous work using pupillometry. The primary outcome is a measure of delirium in the recovery room and secondary outcomes include total length of stay, intensive care unit (ICU) length of stay, and readmissions within 30 days of surgery.

NCT ID: NCT05578859 Completed - Healthy Subjects Clinical Trials

A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects

Start date: March 11, 2020
Phase: Phase 1
Study type: Interventional

The primary objectives of the study are: to characterize the primary route(s) of elimination of [14C]-AMG 510 and drug-related material, and estimate the overall recovery of radiolabeled material in healthy male participants after oral administration of [14C]-AMG 510, and to characterize the pharmacokinetic (PK) of total radioactivity and AMG 510 following a single oral dose of [14C]-AMG 510 in healthy male participants.

NCT ID: NCT05578846 Completed - Clinical trials for Healthy Adult Participants

Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

Start date: October 13, 2022
Phase: Phase 1
Study type: Interventional

This study will assess the Bioequivalence between 180 mg and 60 mg ALXN2050 Tablets and the Effect of Food on ALXN2050 Pharmacokinetics.

NCT ID: NCT05578599 Completed - Ventilated Patients Clinical Trials

A Pilot Study Swiftsure

Start date: October 12, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the feasibility of using the Swiftsure Complete Care System (CCS) device as an adjunct to standard oral care procedures among intubated adult patients undergoing mechanical ventilation in the intensive care unit (ICU). This is a small study intended to gather initial feasibility before conducting a larger study. The feasibility of using the Swiftsure CSS device will be studied among 20 patients at a single study site.

NCT ID: NCT05577728 Completed - Clinical trials for Diabetes Mellitus, Type 2

Replication of the SEPRA Diabetes Trial in Healthcare Claims Data

Start date: July 1, 2021
Phase:
Study type: Observational

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.